Last €27.19 EUR
Change Today -0.39 / -1.41%
Volume 28.0K
ERYP On Other Exchanges
EN Paris
As of 9:41 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

erytech pharma (ERYP) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/1/14 - €34.97
52 Week Low
12/23/13 - €9.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ERYTECH PHARMA (ERYP)

Related News

No related news articles were found.

erytech pharma (ERYP) Related Businessweek News

No Related Businessweek News Found

erytech pharma (ERYP) Details

ERYTECH Pharma, société anonyme develops cancer therapies. The company’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. It is developing ERY-ASP that consists of red blood cell-encapsulated L-asparaginase, which destroys asparagine inside the red blood cell, preventing allergic reactions and reducing other adverse events. The company is developing ERY-ASP for the treatment of acute lymphoblastic leukaemia, acute myeloid leukaemia, and solid tumours. The company was founded in 2004 and is headquartered in Lyon, France.

37 Employees
Last Reported Date: 08/29/14
Founded in 2004

erytech pharma (ERYP) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €164.7K
Co-Founder, Chief Scientific Officer, Deputy ...
Total Annual Compensation: €240.0K
Co-Founder, Vice President of the Board of Di...
Total Annual Compensation: €240.8K
Director of Pharmaceutical Operations and Dep...
Total Annual Compensation: €60.3K
Regulatory Affairs Director and General Manag...
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

erytech pharma (ERYP) Key Developments

Erytech Announces Additional Positive Phase III Results from Clinical Study with ERY-ASP/GRASPA

Erytech announced that it develops innovative “tumor starvation” treatments for acute leukemia and other oncology indications with unmet medical needs, reports additional positive Phase III results from the pivotal study with ERY-ASP/GRASPA® in Acute Lymphoblastic Leukemia. Positive top-line data of the study were made available end of September, and demonstrated that the Phase III GRASPIVOTALL clinical trial met both of its primary endpoints. A significant reduction of clinical hypersensitivity was observed with ERY-ASP/GRASPA (development name: ERY001) while maintaining asparaginase activity longer than with native L-asparaginase (L-ASP) in the control arm. The study also showed favorable results in patients with prior allergies to asparaginase, both in terms of hypersensitivities and asparaginase activity. Additional study results based on the pre-specified key secondary endpoints were presented and discussed at an investigator meeting in connection with the annual meeting of the American Society of Hematology (ASH) in San Francisco. It is worth noting that the study was not powered to demonstrate statistical significance on any of the secondary parameters. A significantly improved complete remission (CR) rate and a trend towards increased overall and event-free survival (OS and EFS) with ERY001 compared to native L-asparaginase (L-ASP). Median OS and EFS have not been reached; abetter overall safety profile, notably with improved clotting parameters (coagulation disorders), in addition to lower hypersensitivity reactions (no allergic reactions with ERY001 versus 43% with L-ASP, with 25% Grade 3 or above); neither the risk status nor the age of the patients (children versus adults) had an influence on the study outcome; favorable results also in the patients with prior hypersensitivities to asparaginase (exploratory ‘HypSen’ arm) who could not be randomized to native asparaginase.

ERYTECH to Report Positive Initial Results on the Use of GRASPAA in ALL Patients Allergic to E. Coli and Erwinia Derived Asparaginases at ASH

ERYTECH announced the presentation of four case studies with GRASPA(Registered) in an expanded access program at the 56th Annual Meeting of the American Society of Hematology (ASH), December 6-9, 2014, in San Francisco, CA. The expanded access program (#NCT02197650) was set up to provide access to GRASPA(Registered) to patients with acute lymphoblastic leukemia (ALL), in first line or relapse, who are at risk of hypersensitivity reactions due to previous allergies to both the E. Coli and Erwinia derived asparaginases. The first results of this program indicate reduced hypersensitivity reactions in these 'double allergic' patients while maintaining adequate asparaginase activity and they bring additional confirmation of GRASPA (Registered)'s reduced immunotoxicity, also in patients with prior allergies to E. Coli derived asparaginase, as was recently demonstrated in the top-line Phase III results in relapsed ALL patients.

ERYTECH Reports Positive Top-Line Phase III Results from Clinical Study with GRASPA in Acute Lymphoblastic Leukemia

ERYTECH reports positive Phase III results from its pivotal study with GRASPA in Acute Lymphoblastic Leukemia. Analysis of the primary and first secondary efficacy endpoints of the GRASPALL clinical trial with one year follow up shows that the GRASPIVOTALL (GRASPALL2009-06) clinical trial convincingly meets both of its primary endpoints, and that the secondary efficacy endpoints analyzed so far confirm the favorable clinical efficacy profile of GRASPA. The study also shows favorable results in patients with prior allergies to L-asparaginase. The GRASPIVOTALL study is a controlled, multicenter Phase II/III trial with 80 children and adults suffering from relapsing or refractory Acute Lymphoblastic Leukemia (ALL) with three arms. The first two arms compare GRASPA to native E. Coli L-asparaginase, both in combination with standard chemotherapy (COOPRALL), in a 1-to-1 randomization in patients without prior allergies to L-asparaginase. The third arm is an open label assessment of GRASPA for patients who have experienced allergic reactions related to asparaginase in their first line treatment. The primary endpoint of the study consisted of two objectives, in accordance with CHMP(1) advice: a) superior safety, expressed as a significant reduction of the incidence of allergic reactions with GRASPA compared to the control group, and b) non-inferior duration of asparaginase activity above the threshold of 100 IU/l during the induction phase in the non-allergic patients. Both endpoints needed to be met for the study to be considered positive. The main secondary efficacy endpoints included the assessment of clinical parameters such as complete remission (CR), minimal residual disease (MRD), event-free survival (EFS) and overall survival (OS). Primary endpoints met - Statistically significant reduction of allergic reactions: none of the 26 patients in the GRASPA arm experienced an allergic reaction versus 12 of the 28 (42.9%) patients treated with reference L-asparaginase in the control group (p<001). Statistically significant increase in duration of circulating asparaginase activity: in the GRASPA group, asparaginase levels were maintained above 100 IU/l for an average of 20.5 days with up to 2 injections during the first month of treatment (induction phase) versus 9.2 days in the control group with up to 8 injections of reference L-asparaginase (p<001). Secondary endpoints confirm the favorable clinical efficacy of GRASPA - At the end of the induction phase, 15 patients (71.4%) in the GRASPA arm show complete remission versus 11 patients (42.3%) in the control arm. GRASPA well tolerated by patients with previous allergies to L-asparaginase - A favorable clinical profile was seen in patients with prior allergies to L-asparaginase with only 2 patients experiencing mild allergic reactions. These results confirm earlier observations with GRASPA in a Phase I/II randomized dose escalation study in 24 relapsing ALL patients, and a Phase II study in first line ALL patients over 55 years of age. Further analysis of additional secondary and exploratory endpoints is ongoing. Results will be available later this year and are planned to be presented at an upcoming scientific conference. A Phase IIb study with GRASPA in Acute Myeloid Leukemia (AML) is progressing well with more than half of the patients enrolled and a Phase II study in pancreatic cancer has been launched earlier this year. Building on these positive results with GRASPA in ALL, the company plans to accelerate the development in ALL in the US and to launch Phase II clinical trials in additional oncology indications with high unmet medical need.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ERYP:FP €27.19 EUR -0.39

ERYP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ERYP.
View Industry Companies

Industry Analysis


Industry Average

Valuation ERYP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 91.1x
Price/Book 12.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 102.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ERYTECH PHARMA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at